[go: up one dir, main page]

WO1999034830A1 - Preparations ophtalmiques topiques contenant des agents immunosuppresseurs - Google Patents

Preparations ophtalmiques topiques contenant des agents immunosuppresseurs Download PDF

Info

Publication number
WO1999034830A1
WO1999034830A1 PCT/CZ1998/000054 CZ9800054W WO9934830A1 WO 1999034830 A1 WO1999034830 A1 WO 1999034830A1 CZ 9800054 W CZ9800054 W CZ 9800054W WO 9934830 A1 WO9934830 A1 WO 9934830A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparations
weight
immunosuppressive agents
ciclosporin
cornea
Prior art date
Application number
PCT/CZ1998/000054
Other languages
English (en)
Inventor
Milan Stuchlík
Alexandr Jegorov
Vladimír MAŤHA
Josef Stuchlík
Original Assignee
Galena, A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galena, A.S. filed Critical Galena, A.S.
Priority to AU14813/99A priority Critical patent/AU1481399A/en
Priority to HR20000258A priority patent/HRP20000258A2/hr
Priority to JP2000527277A priority patent/JP2002500200A/ja
Priority to PL98341604A priority patent/PL341604A1/xx
Priority to HU0004173A priority patent/HUP0004173A2/hu
Priority to EP98958793A priority patent/EP1058560A1/fr
Priority to CA002317010A priority patent/CA2317010A1/fr
Publication of WO1999034830A1 publication Critical patent/WO1999034830A1/fr
Priority to BG104558A priority patent/BG104558A/xx
Priority to NO20003344A priority patent/NO20003344L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • the present invention describes therapeutic preparations for topical ophthalmic application, which are characterised by the presence of from 0.02 to 5.0 weight % of immunosuppressive agents, dissolved or dispersed in physiologically acceptable vehicles comprising up to 10 weight % of polyalkyleneglycol-polyurethane copolymers of general formula I
  • the appended drawings are graphic illustrations of the effects of the addition of 1 % of the PPG-51/SMDI copolymer to topical ophthalmic preparations of Example 3 on abso ⁇ tion of ciclosporin into the cornea (diagram 1) and its penetration into the iris (diagram 2), into the aqueous humour (diagram 3) and into the uvea (diagram 4).
  • a significant increase in abso ⁇ tion occurred in the groups of pigmented male and female rabbits.
  • the average increase of the ciclosporin concentration following 12 administrations of 1 drop each was as follows: cornea, 3.30 x; iris, 5.24 x; aqueous humour, 5.08 x; and uvea, 5.2 x.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention se rapporte à des préparations thérapeutiques conçues pour l'application ophtalmique topique, qui contiennent de 0,02 à 5 % en poids d'agents immunosuppresseurs appartenant aux groupes des undécapeptides monocycliques, des lactones macrolides et des corticostéroïdes, dans un excipient comportant jusqu'à 10 % en poids de copolymères de polyalkylèneglycol-polyuréthane. Lesdits copolymères sont constitués de préférence de poly(oxy-1,2-éthanediyl)-α-hydro-φ-hydroxypolymères associés à du 1,1'-méthylène-bis-(4-isocyanatocyclohexane) de poids moléculaire moyen compris entre 1000 et 3000 dans un excipient hydrophile et de préférence de poly(oxy-1,2-méthyl)-α-hydro-φ-hydroxypolymères associés à du 1,1'-méthylène-bis-(4-isocyanatocyclohexane) de poids moléculaire moyen compris entre 1600 et 18000 dans un excipient lipophile. Lesdits agents thérapeutiques peuvent également contenir des excipients supplémentaires habituellement utilisés dans les formulations pour application topique.
PCT/CZ1998/000054 1997-12-30 1998-12-17 Preparations ophtalmiques topiques contenant des agents immunosuppresseurs WO1999034830A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU14813/99A AU1481399A (en) 1997-12-30 1998-12-17 Topical ophthalmic preparations containing immunosuppressive agents
HR20000258A HRP20000258A2 (en) 1997-12-30 1998-12-17 Topical ophthalmic preparations containing immunosuppressive agents
JP2000527277A JP2002500200A (ja) 1997-12-30 1998-12-17 免疫抑制剤を含む局所眼科治療薬
PL98341604A PL341604A1 (en) 1997-12-30 1998-12-17 Local application ophthalmic preparations containing immunossuppressive agents
HU0004173A HUP0004173A2 (hu) 1997-12-30 1998-12-17 Immunszuppresszív szereket tartalmazó, helyileg alkalmazható szemgyógyászati készítmények
EP98958793A EP1058560A1 (fr) 1997-12-30 1998-12-17 Preparations ophtalmiques topiques contenant des agents immunosuppresseurs
CA002317010A CA2317010A1 (fr) 1997-12-30 1998-12-17 Preparations ophtalmiques topiques contenant des agents immunosuppresseurs
BG104558A BG104558A (en) 1997-12-30 2000-06-27 Topical ophthalmic preparations containing immunosuppressive agents
NO20003344A NO20003344L (no) 1997-12-30 2000-06-27 Topiske øyepreparater inneholdende immunosuppressive midler

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZPV4237-97 1997-12-30
CZ19974237A CZ287497B6 (cs) 1997-12-30 1997-12-30 Topické oční přípravky s imunosupresivními látkami

Publications (1)

Publication Number Publication Date
WO1999034830A1 true WO1999034830A1 (fr) 1999-07-15

Family

ID=5467853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ1998/000054 WO1999034830A1 (fr) 1997-12-30 1998-12-17 Preparations ophtalmiques topiques contenant des agents immunosuppresseurs

Country Status (12)

Country Link
EP (1) EP1058560A1 (fr)
JP (1) JP2002500200A (fr)
AU (1) AU1481399A (fr)
BG (1) BG104558A (fr)
CA (1) CA2317010A1 (fr)
CZ (1) CZ287497B6 (fr)
HR (1) HRP20000258A2 (fr)
HU (1) HUP0004173A2 (fr)
NO (1) NO20003344L (fr)
PL (1) PL341604A1 (fr)
SK (1) SK284246B6 (fr)
WO (1) WO1999034830A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038703A1 (fr) * 1998-12-24 2000-07-06 R-Tech Ueno, Ltd. Agent permettant le traitement d'un trouble fonctionnel de cellules de la vision
WO2003017990A3 (fr) * 2001-08-23 2003-08-28 Novartis Ag Compositions ophtalmiques
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
WO2005011813A3 (fr) * 2003-07-31 2005-04-28 Gholam A Peyman Traitement de trouble oculaire
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7585517B2 (en) 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US7833966B2 (en) 2005-07-18 2010-11-16 Peyman Gholam A Enhanced ocular neuroprotection and neurostimulation
US8163726B2 (en) 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
US8486960B2 (en) 2006-03-23 2013-07-16 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8658667B2 (en) 2006-02-09 2014-02-25 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
WO2014153733A1 (fr) * 2013-03-27 2014-10-02 Comprehensive Drug Enterprises, Ltd. Composition ophtalmique, son procédé de préparation et son utilisation
US8927005B2 (en) 2005-02-09 2015-01-06 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2948134T3 (da) 2013-01-24 2020-06-02 Palvella Therapeutics Inc Sammensætninger til transdermal indgivelse af mtor-inhibitorer
CN109071750B (zh) 2016-03-08 2022-08-02 生活实验公司 持久化妆品组合物
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
CA3074843A1 (fr) 2017-09-13 2019-03-21 Living Proof, Inc. Compositions cosmetiques longue duree
CN111065665B (zh) 2017-09-13 2023-03-17 生活实验公司 颜色保护剂组合物
EP3713646A1 (fr) 2017-11-20 2020-09-30 Living Proof, Inc. Propriétés permettant d'obtenir des performances cosmétiques de longue durée
WO2019210121A1 (fr) 2018-04-27 2019-10-31 Living Proof, Inc. Compositions cosmétiques longue durée
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971800A (en) * 1988-07-08 1990-11-20 The Regents Of The University Of California Method and compositions for enhancing the cutaneous penetration of pharmacologically active agents
US5045317A (en) * 1987-07-16 1991-09-03 The Regents Of The University Of California Enhancing the cutaneous penetration of pharmacologically active agents
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045317A (en) * 1987-07-16 1991-09-03 The Regents Of The University Of California Enhancing the cutaneous penetration of pharmacologically active agents
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
US4971800A (en) * 1988-07-08 1990-11-20 The Regents Of The University Of California Method and compositions for enhancing the cutaneous penetration of pharmacologically active agents

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
AU781049B2 (en) * 1998-12-24 2005-05-05 Sucampo Ag Agent for treating visual cell function disorder
WO2000038703A1 (fr) * 1998-12-24 2000-07-06 R-Tech Ueno, Ltd. Agent permettant le traitement d'un trouble fonctionnel de cellules de la vision
CN100366251C (zh) * 2001-08-23 2008-02-06 诺瓦提斯公司 包含子囊霉素的眼用组合物
WO2003017990A3 (fr) * 2001-08-23 2003-08-28 Novartis Ag Compositions ophtalmiques
AU2002331172B2 (en) * 2001-08-23 2005-12-01 Novartis Ag Ophthalmic composition comprising an ascomycin
US8618088B2 (en) 2002-09-18 2013-12-31 University Of Pennsylvania Methods of inhibiting choroidal neovascularization
US8163726B2 (en) 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
WO2005011813A3 (fr) * 2003-07-31 2005-04-28 Gholam A Peyman Traitement de trouble oculaire
US7585517B2 (en) 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US9381153B2 (en) 2005-02-09 2016-07-05 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US9387165B2 (en) 2005-02-09 2016-07-12 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US8927005B2 (en) 2005-02-09 2015-01-06 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US7833966B2 (en) 2005-07-18 2010-11-16 Peyman Gholam A Enhanced ocular neuroprotection and neurostimulation
US8202840B2 (en) 2005-07-18 2012-06-19 Minu L.L.C. Enhanced ocular neuroprotection and neurostimulation
US8658667B2 (en) 2006-02-09 2014-02-25 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US8486960B2 (en) 2006-03-23 2013-07-16 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US9452156B2 (en) 2006-03-23 2016-09-27 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
WO2014153733A1 (fr) * 2013-03-27 2014-10-02 Comprehensive Drug Enterprises, Ltd. Composition ophtalmique, son procédé de préparation et son utilisation

Also Published As

Publication number Publication date
EP1058560A1 (fr) 2000-12-13
NO20003344D0 (no) 2000-06-27
PL341604A1 (en) 2001-04-23
HUP0004173A2 (hu) 2001-08-28
BG104558A (en) 2001-02-28
AU1481399A (en) 1999-07-26
CZ287497B6 (cs) 2000-12-13
JP2002500200A (ja) 2002-01-08
SK171798A3 (en) 1999-10-08
CA2317010A1 (fr) 1999-07-15
NO20003344L (no) 2000-06-27
HRP20000258A2 (en) 2001-04-30
SK284246B6 (sk) 2004-12-01
CZ423797A3 (cs) 1999-07-14

Similar Documents

Publication Publication Date Title
WO1999034830A1 (fr) Preparations ophtalmiques topiques contenant des agents immunosuppresseurs
US11324757B2 (en) Pharmaceutical composition for treatment of increased intraocular pressure
Shen et al. Preparation and ocular pharmacokinetics of ganciclovir liposomes
EP3000474B1 (fr) Composition de goutte oculaire de nano-émulsion contenant de la cyclosporine et son procédé de préparation
US5951971A (en) Ophthalmic compositions
Pleyer et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye.
CN116133639A (zh) 用于治疗炎性疾病的制剂和方法
SK285220B6 (sk) Oftalmologické prostriedky
HK1004520B (en) Ophthalmic compositions containing a cyclosporin
CN112516084A (zh) 含有环孢素胶束的原位凝胶作为缓释眼科药物递送系统
US20150045309A1 (en) Cyclosporin emulsions
KR20150000405A (ko) 난용성 의약품의 수중유적형 에멀젼 조성물 및 이의 제조방법
US7053061B2 (en) Amphotercin B structured emulsion
MXPA00006508A (en) Topical ophthalmic preparations containing immunosuppressive agents
RU2634267C2 (ru) Водный офтальмологический раствор на основе циклоспорина a

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998958793

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P20000258A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 09582018

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2317010

Country of ref document: CA

Kind code of ref document: A

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/006508

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998958793

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998958793

Country of ref document: EP